乳腺癌分子医学专题 |
|
|
|
|
CD97免疫表位对乳腺癌细胞株MDA-MB231生物学行为的影响 |
田华, 陈洋, 赵建刚, 刘达人, 梁刚, 龚谓华, 陈力, 吴育连 |
浙江大学医学院附属第二医院外科, 浙江 杭州 310009 |
|
Effects of siRNAs targeting CD97 immune epitopes on biological behavior in breast cancer cell line MDA-MB231 |
TIAN Hua, CHEN Yang, ZHAO Jiangang, LIU Daren, LIANG Gang, GONG Weihua, CHEN Li, WU Yulian |
Department of General Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China |
引用本文:
田华 等. CD97免疫表位对乳腺癌细胞株MDA-MB231生物学行为的影响[J]. 浙江大学学报(医学版), 2017, 46(4): 341-348.
TIAN Hua, CHEN Yang, ZHAO Jiangang, LIU Daren, LIANG Gang, GONG Weihua, CHEN Li, WU Yulian. Effects of siRNAs targeting CD97 immune epitopes on biological behavior in breast cancer cell line MDA-MB231. Journal of ZheJiang University(Medical Science), 2017, 46(4): 341-348.
链接本文:
http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2017.08.01
或
http://www.zjujournals.com/xueshu/med/CN/Y2017/V46/I4/341
|
[1] MUNK C, ISBERG V, MORDALSKI S, et al. GPCRdb:the G protein-coupled receptor database-an introduction[J]. Br J Pharmacol,2016,173(14):2195-2207.
[2] PIERCE K L, PREMONT R T, LEFKOWITZ R J. Seven-transmembrane receptors[J]. Nat Rev Mol Cell Biol,2002,3(9):639-650.
[3] NIJMEIJER S, VISCHER H F, LEURS R. Adhesion GPCRs in immunology[J]. Biochem Pharmacol,2016,114:88-102.
[4] LIU D, TROJANOWICZ B, RADESTOCKY, et al. Role of CD97 isoforms in gastric carcinoma[J]. Int J Oncol,2010,36(6):1401-1408.
[5] HOANG-VU C, BULL K, SCHWARZI, et al. Regulation of CD97 protein in thyroid carcinoma[J]. J Clin Endocrinol Metab,1999,84(3):1104-1109.
[6] WOBUS M, VOGEL B, SCHMVCKING E, et al. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding[J]. Int J Cancer,2004,112(5):815-822.
[7] 袁晓雷,田华,朱旭明,等.CD97-CD55蛋白复合体在乳腺恶性肿瘤组织中的表达及临床意义[J].浙江医学,2014,36(11):928-936. YUAN Xiaolei, TIAN Hua, ZHU Xuming, et al. Expression of CD97-CD55 protein complex in patients with breast malignant tumors and its clinicopathological significance[J]. Zhejiang Medical Journal,2014,36(11):928-936. (in Chinese)
[8] CHEN X, DUAN N, ZHANG C, et al. Survivin and tumorigenesis:molecular mechanisms and therapeutic strategies[J]. J Cancer,2016,7(3):314-323.
[9] HANAHAN D, WEINBERGR A. Hallmarks of cancer:the next generation[J]. Cell,2011,144(5):646-674.
[10] KRISHNA P S, NAGARE R P, SNEHA V S, et al. Tumour angiogenesis-origin of blood vessels[J]. Int J Cancer,2016,139(4):729-735.
[11] GUIDO C, WHITAKER-MENEZES D, CAPPARELLI C, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth:connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production[J]. Cell Cycle,2012,11(16):3019-3035.
[12] YU J S, CUI W. Proliferation, survival and metabolism:the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination[J]. Development,2016,143(17):3050-3060.
[13] GORDON S, HAMANN J, LIN H H, et al. F4/80 and the related adhesion-GPCRs[J]. Eur J Immunol,2011,41(11):2472-2476.
[14] SAFAEE M, CLARK A J, IVAN M E, et al. CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review)[J]. Int J Oncol,2013,43(5):134313-50.
[15] HSIAO C C, CHENG K F, CHEN H Y, et al. Site-specific N-glycosylation regulates the GPS auto-proteolysis of CD97[J]. FEBS Lett,2009,583(19):3285-3290. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|